Meeting
2022 ASCO Annual Meeting
Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo).
Authors
Sana Ali
Harbor-UCLA Medical Center, Torrance, CA
Sana Ali , Sally Leong , Luis A Meza , Nazli Dizman , Zeynep Busra Zengin , Tane Kim , Youngju Pak , Mykola Onyshchenko , Sumanta K. Pal , Alex Chehrazi-Raffle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4554)
DOI
10.1200/JCO.2022.40.16_suppl.4554
Abstract #
4554
Poster Bd #
45
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).
First Author: Connor Wells
Poster
2023 ASCO Genitourinary Cancers Symposium
Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).
First Author: Sally Leong
Poster
2021 Genitourinary Cancers Symposium
Treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma (mRCC) using real-world data.
First Author: Daniel M. Geynisman
Poster
2024 ASCO Genitourinary Cancers Symposium
Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
First Author: Regina Barragan-Carrillo